What Happened?
Shares of healthcare company Surgery Partners (NASDAQ: SGRY) jumped 3.3% in the morning session after an analyst at investment firm Benchmark reiterated a "Buy" rating and a $35 price target on the company's stock.
The positive sentiment from the analyst comes after a period of volatility for the surgical facilities operator. In June, the company announced it had concluded acquisition talks with private equity firm Bain Capital, opting to remain independent after determining the offer undervalued the company's potential. Despite the failed takeover, several analyst firms have maintained their positive outlooks, pointing to the company's growth prospects in the outpatient surgical care market. Surgery Partners operates a large network of ambulatory surgery centers and surgical hospitals, a sector benefiting from the ongoing shift of medical procedures out of traditional hospital settings. The reiterated Buy rating suggests confidence in the company's standalone strategy and its ability to generate value for shareholders.
After the initial pop the shares cooled down to $22.34, up 2.2% from previous close.
Is now the time to buy Surgery Partners? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Surgery Partners’s shares are somewhat volatile and have had 12 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 3 months ago when the stock dropped 6.1% after President Trump criticized the Federal Reserve's approach to interest rate cuts, warning that the pace was slow and could hinder economic growth.
Trump's comments added pressure to an already sensitive market, raising concerns about political interference in monetary policy.
Meanwhile, Fed Chair Jerome Powell maintained a cautious stance the previous week, highlighting the difficulty of balancing the dual mandate of steady employment and price stability amid the escalating trade tension.
Investor sentiment was further dampened by the absence of constructive progress in trade negotiations, especially US-China relations which took a turn for the worse in the previous week.
Overall, the outlook seemed more unclear heading into the first quarter 2025 earnings season, as a combination of hard to predict monetary policy and unresolved trade tensions weighed on business confidence.
Surgery Partners is up 4.9% since the beginning of the year, but at $22.34 per share, it is still trading 33.7% below its 52-week high of $33.69 from August 2024. Investors who bought $1,000 worth of Surgery Partners’s shares 5 years ago would now be looking at an investment worth $1,519.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
